Muscle bulk in adult healthy humans is highly variable even after accounting for height, age and 30 sex. Low muscle mass, due to fewer and/or smaller constituent muscle fibres, would exacerbate 31 the impact of muscle loss occurring in aging or disease. Genetic variability substantially influences 32 muscle mass differences, but causative genes remain largely unknown. In a genome-wide 33 association study (GWAS) on appendicular lean mass (ALM) in a population of 95,545 middle-age 34 (37-48 years) individuals from the UK Biobank we found 125 loci associated with ALM (P<5x10 -8 ). 35
Introduction 45
Skeletal muscle plays key roles in locomotion, respiration, thermoregulation, maintenance 46 of glucose homeostasis and protection of bones and viscera. The loss of muscle due to aging, known as sarcopenia, affects mobility and can lead to frailty and deterioration of quality of life 1 . The 48 risk of disability is 1.5 to 4.6 times higher in the sarcopenic elderly than in the age matched 49 individuals with normal muscle mass 2 . However, lean mass, a non-invasive proxy for muscle mass, 50 differs by more than two-fold between healthy adult individuals of same sex, age and height 3 . 51
Therefore, we hypothesize that differential accretion of muscle mass by adulthood may influence 52 the risk of sarcopenia and frailty later in life. 53
Genetic factors contribute substantially to the variability in lean mass in humans, with 54 heritability estimates of 40 -80 % 4 . A continuous distribution of the trait and data obtained from 55 animal models 5-7 indicates a polygenic causality. However, thus far, genome-wide association 56 studies (GWAS) have implicated fewer than a dozen genes, explaining only a small fraction of this 57 heritability 8; 9 . A limited sample size in early studies 10-14 and the effects of confounders such as 58 subject age 8 , size of the skeleton and composition of lean mass have hindered detection of genes. 59
The UK Biobank is a resource of demographic, phenotypic and genotypic data collected on 60 ~500,000 individuals 15 . It includes the arm and leg lean mass, body composition and morphometric 61 information, providing a model for improving our understanding of the genetic basis for variability in 62 muscle mass. Skeletal muscle mass, however, changes over the course of individual's lifespan. It 63 reaches a peak around mid-twenties and remains largely stable through mid-fourties, before 64 succumbing to gradual decline, which accelerates after about 70 years of age 16 . There is a 65 substantial degree of individual variability in the slope of muscle change across both the increasing 66 and decreasing phases of the lifespan trajectory 17 . Both the trajectory itself and the slope of 67 individual variability may impede identification of genes. 68
The indirect estimates of lean mass impose limitations because muscle mass is not an 69 exclusive contributor to this variable. Furthermore, the cellular basis of variability in muscle mass 70 (i.e. if it is caused by the differences in the number of constituent muscle fibres, their size, or both) 71 remains completely latent. Using the laboratory mouse circumvents a number of those limitations. 72
The mouse shares approximately 90% of the genome with humans 18 , and permits analyses of 73 traits not amenable in humans, such as muscle mass 6; 7; 19 and muscle fibre characteristics 20; 21 . 74 The phenotypic differences between the LG/J and SM/J mouse strains make them particularly 75 attractive for complex trait analyses [22] [23] [24] . LG/J mice were selected for large body size 25 , while SM/J 76 mice were selected for small body size 26 . The F2 intercross derived from the LG/J and SM/J strains 77 (LGSM) 6; 27 and an advanced intercross line (AIL) of the LGSM (LGSM AIL) developed using a 78 breeding strategy proposed by Darvasi and Soler 28 , led to multiple quantitative trait loci (QTLs) for 79 muscle mass 6; 27 . However, these QTLs still encompass tens or even hundreds of genes and 80 require further prioritising. We hypothesized that the detection power of a modest sample size of 81 the LGSM AIL and the superior resolution of a human cohort will facilitate identification of the 82 quantitative trait genes (QTGs) underlying muscle QTLs. 83
The aim of this study was to identify the genomic loci and the underlying genes for 84 variability in skeletal muscle mass and to assess their effects in the elderly. We addressed this in 85 three stages: (1) we conducted a GWAS in a human cohort of middle-aged individuals from the UK 86 Biobank, and tested the effect of the identified set of loci in an elderly cohort; (2) we conducted a 87 GWAS on hindlimb muscle mass in a population of LGSM AIL mice. The population in this study consisted of 316,589 adult individuals of 37 to 74 years of age 94 (project ID: 26746). We drew this cohort from the UK Biobank (UKB) project 15 ; all participants 95 recruited were identified from the UK National Health Service (NHS) records and attended a 96 baseline visit assessment between 2006 and 2010. During the assessment, participants gave 97 written consent, answered a questionnaire, and were interviewed about their health and lifestyle. 98
Blood samples and anthropometric measurements were collected from each participant. 99
Assessments were conducted at 22 facilities in Scotland, England, and Wales. 100
We divided the sample into middle-aged and elderly cohorts. The middle-aged cohort 101 consisted of 99,065 adults ranging from 37 to 48 years of age; these individuals were not affected 102 by sarcopenia. We excluded 3,520 participants that were reported to be ill with cancer, pregnant, 103 or had undergone a leg amputation procedure, as well as individuals with discordant genetic sex 104 and self-reported sex records. We retained a total of 95,545 adult individuals (51,394 females and 105 44,151 males) for further analyses. 106
The elderly cohort consisted of 217,524 adults ranging from 63 to 74 years of age. We 107 selected this cohort to test if the effect of the genetic variants identified on middle-aged individuals 108 could also influenced phenotypes later in life. We excluded 23,836 individuals based on the same 109 criteria used for the middle-aged cohort. After exclusions, the elderly cohort included 193,688 110 individuals of 63 to 74 years of age (100,463 females and 93,225 males) (Table S1) . 111 112 UK biobank traits 113 We used the data for standing height (UKB field ID: 50), sitting height (UKB field ID: 114 20015), whole body fat (UKB field ID: 23100), arm lean mass (UKB field ID: 23121 and 23125), 115 and leg lean mass (UKB field ID: 23113 and 23117) measured as part of the UK Biobank project. 116 Body composition measurements were taken using bioelectric impedance. We calculated leg 117 length by subtracting sitting height from standing height (all measurements were recorded in cm). 118
Because lean mass in the limbs primarily consists of skeletal muscle tissue, we used ALM as a 119 proxy for muscle mass. We calculated ALM as the sum of the muscle mass of two arms and two 120 legs. We checked that all traits were normally distributed by examining the QQ-plot and histogram 121 of residuals from a simple linear model that included sex as a covariate. Residuals were normally 122 distributed and we did not transform any of the traits. 123 124 UK biobank genotypes 125 We obtained genotype data for all participants from the UKB v3 genotypes release 29 , which 126 includes genotype calls from the Affymetrix UK BiLEVE Axiom array and the Affymetrix UK 127 Biobank Axiom array. IMPUTE2 29 was used to impute genotypes from the UK10K and 1000 128
Genomes Phase 3 reference panels 30 , as described by Brycroft et al 29 . We kept all imputed 129 genotype data (93,095,624 genetic variants (SNPs, Indels and structural variants)) for subsequent 130 analyses in order to capture the effects of both common (MAF > 0.001) and rare variants (MAF < 131 0.001). The software (BOLT-LMM v2.3.2) 31 we used to perform GWAS was developed for large 132 data sets (i.e.: UK Biobank cohort) and it was only tested for human cohorts, which have different 133 LD patterns from animals. For these two reasons, we used BOLT-LMM v2.3.2 for the analyses of 134 human data only. Although we mainly focused on reporting the effects of common variants, we 135 also reported rare variants associated with ALM as a supplemental table (Table S4) . 136 137 Appendicular lean mass GWAS 138 We used BOLT-LMM (v2.3.2) 32 to perform a GWAS for ALM in the middle-aged cohort. The 139 linear mixed model (LMM) approach implemented in BOLT-LMM is capable of analysing large data 140 sets while also accounting for cryptic relatedness between individuals. Specifically, BOLT-LMM 141 calibrates the association statistics using a linkage disequilibrium (LD) score regression 142 approach 33 ; this allowed us to evaluate the impact of confounding factors on the GWAS test 143 statistics 33 and calibrate them accordingly. In the absence of confounding factors, p-values should 144 not be inflated, and the LD score regression intercept should be equal to 1 33 . The LD Score 145 regression intercept in this study was 1.043 ± 0.007, suggesting minimal inflation of P values due 146 to linkage between markers. After calibrating the test statistics, the mean  2 of the ALM GWAS 147 was 1.27 and lambda (λGC) or genomic control inflation factor was 1.20 ( Figure S1 ), which 148 indicated polygenicity of the trait as described by Bulik-Sullivan and colleagues 33 . 149
We also assessed population structure by running principal component analysis on the 150 genotype calls. We included sex, leg length, whole body fat, and the first four principal components 151 as fixed effects in the LMM used for the ALM GWAS. Sex was included to account for differences 152 in muscle mass caused by increased testosterone levels in males 34 . Leg length and whole body fat 153 were included because they are biologically related to muscle mass: longer bones result in longer 154 muscles, while fat shares part of its developmental origin with skeletal muscle tissue 35 . 155 Furthermore, each of these traits is correlated with muscle mass. An association was considered 156 statistically significant if its P < 5 × 10 -8 (α = 0.05). This threshold is the standard for GWAS of 157 complex traits 36; 37 . 158
We obtained variance components and SNP heritability estimates of ALM using BOLT-159 To examine the influence of varying age on the genomic loci associated with ALM repeated 166 the analysis using a cohort with a wider age range. To achieve this we subset the middle-aged 167 cohort by randomly selecting 44,727 individuals (37 to 48 years), and likewise, we selected a 168 subset of 44,727 older individuals from the elderly cohort (63 to 74 years) to produce a mixed age 169 population (n = 95,454) (Table S2 ). We used this population to execute a GWAS on ALM using 170 BOLT-LMM, and included sex, age, leg length and whole body fat as fixed effects in our model. We 171 compared the resulting loci (MAF>0.001) (Table S8 ) from this analysis to the ALM loci that we 172 identified on the GWAS conducted exclusively in the middle-aged population of a similar sample 173 size (n=95,454). This analysis was restricted to one iteration due demand for computational 174 resources (~130h per GWAS). 175 176 Phenotypic variance explained by ALM loci 177 We defined ALM genomic loci using the web-based platform Functional Mapping and 178
Annotation of Genome-Wide Association Studies (FUMA GWAS 39 ). A key feature of this tool is the 179 identification of genomic regions based on the provided summary statistic of a GWAS depending 180 on LD structure; this process is automated using pairwise LD of SNPs in the reference panel (1000 181 genomes project phase 3 40 ) previous calculated by PLINK 41 . We provided to FUMA GWAS the 182 summary statistic of our GWAS on ALM with the following parameters: 250kb window (maximum 183 distance between LD blocks), r 2 > 0.6 (minimum r 2 for determining LD with independent genome-184 wide significant SNPs used to determine the limits of significant genomic loci), MAF > 0.001 185 (minimum minor allele frequency to be included in the annotation), P < 5 × 10 -8 (threshold of 186 significance associated variants). In addition, we then performed a stepwise conditional analysis 187 using the software package GCTA 42 to identified extra independent signals within 500kb window; 188 this analysis was conducted only on statistically significant SNPs (P < 5 × 10 -8 ) with MAF > 0.001. 189
We refer to the identified regions and the independent signals as loci throughout the text. 190
We used the top variant (based on the outcome from FUMA 39 and GTCA 42 software 191 packages) (Table S5 ) of each locus identified to estimate the proportion of phenotypic variance 192 explained by each locus. We estimated phenotype residuals using a model that included the fixed 193 effects and principal components described above. We then regressed the residuals on the 194 genotype of the top SNP in a linear model. We estimated the coefficients of determination and 195 reported them as the proportion of phenotypic variance explained by each locus. 196 197 Genetic effects in the elderly cohort 198 We tested the combined effect of all 125 genome-wide significant ALM loci identified in the 199 middle-aged cohort in the elderly cohort using the top SNP at each locus. We used PLINK2 41 to 200 impute genotype dosages for each variant identified in the middle-aged GWAS in the elderly 201 cohort. We then estimated a 'genetic lean mass score' for each individual using the following 202 procedure. First, we estimated the contribution of each variant on the phenotype as a product of 203 the SNP effect size obtained from BOLT-LMM (β, calculated based on the reference allele) and the 204 genotype dosage. Second, we calculated the 'lean mass score' for each individual as the sum of 205 the products for all selected variants. We ranked the resulting distribution of lean mass scores in 206 ascending order and partitioned it into five quantiles. We used ALM without any adjustment (raw 207 ALM) because estimates of effects size already accounted for sex, whole body fat and leg length 208 differences. However, since the raw ALM did not meet the assumption of normality, we used a 209
Kruskal-Wallis test (non-parametrical) to evaluate the difference in the median of the phenotypes 210 between the quantiles, and a Wilcoxon test (non-parametrical) for pairwise comparisons between 211 quantiles. We conducted five replicates of a negative control test that consisted on randomly 212 selecting a subset (n = 125) of non-significant SNPs in the middle-aged cohort and generating 213 'lean mass score' as described above for the elderly cohort, this set of SNPs had MAF > 0.001. 214
We also aimed to replicate the individual variants effects on the ALM of the elderly cohort. 215
We checked normality of ALM in the elderly cohort as described for the middle-aged cohort. We 216 tested a subset of genetic variants (n=17,988,060) selected based on their MAF > 0.001 and we 217 used the same LMM, fixed covariates, and genome-wide significance threshold (P < 5 × 10 -8 ) as 218 described for the middle-aged cohort. We conducted a Fisher's exact test to evaluate if overlapping 219 loci between the middle-aged and elderly cohorts were significantly different from random. The null 220 hypothesis was rejected at P < 0.05 (two-tailed). LGSM AIL mouse cohort and GWAS 231 We used three LGSM AIL mouse cohorts for the second stage of this study (n = 1,867). 232
The LGSM AIL was initiated by Dr. James Cheverud at Washington University in St. Louis 49 . 233 Cohort 1 included 490 mice (253 males and 237 females) from LGSM F34. Phenotype data was 234 collected from these mice between 80-102 days of age. Cohort 2 consisted of 506 male mice from 235 F50-54. Cohort 3 includes 887 mice (447 males and 440 females) from F50-56; with age 64 to 111 236 days of age. Mice were housed at room temperature (70 -72°F) at 12:12 h light-dark cycle, with 1-237 4 same-sex animals per cage and with ad libitum access to standard lab chow and water. 238 239 Mouse traits and genotypes 240 We collected muscle phenotypes after the animals were sacrificed and frozen. We 241 dissected four muscles and one long bone (tibia or femur) from each mouse at the Pennsylvania 242 State University (n = 584) and the University of Aberdeen (n = 1,283). The dissection procedure 243 involved defrosting the carcasses and removing the muscles (TA, EDL, gastrocnemius and soleus) 244 and tibia from the hind limbs under a dissection microscope. We weighed the muscles to 0.1-mg 245 precision on a Pioneer balance (Pioneer, Ohaus) and measured bone length (mm) using an 246 electronic digital calliper (Powerfix, Profi). We quantile normalized all LGSM AIL traits before 247 mapping QTLs. 248 Cohort 1 was genotyped using a custom SNP genotyping array 50 . These SNPs (n=2,965) 249 were evenly distributed along the autosomes (mm8, build 36). The median distance between 250 adjacent SNPs was 446 Kb, and the maximum was 18 Mb. Cohort 2 was genotyped at 75,746 251
SNPs (73,301 on the autosomes and 2,386 on X and Y) using the MEGA Mouse Universal 252 Genotyping Array (MegaMUGA; mm9, build 37); we retained 7,168 autosomal SNPs for 253 subsequent analyses. The median distance between adjacent SNPs was 126.9 Kb and the 254 maximum distance was 15 Mb for all chromosomes except for chromosomes 8, 10, and 14, which 255 had distances of 19, 16, and 16 Mb, respectively. We used a conversion tool in Ensembl to convert 256 SNP positions from mm8 (build 36) and mm9 (build 37) to mm10 (build 38). Cohort 3 genotypes 257 were obtained from Gonzales and colleges 51 . These genotypes were generated using genotyping 258 by sequencing. This approach has been recently used and described in detail 19 . Only autosomal 259 SNPs known to be polymorphic in the LG/J and SM/J founder strains (n=523,027; mm10, build 38) 260 were retained for subsequent analyses. We combined the genotype data from Cohorts 1-3 using 261 PLINK v.1.9 and imputed missing genotypes using BEAGLE v.4.1 52 . For these steps, we used a 262 reference panel obtained from Heather Lawson's whole genome sequencing data of the LG/J and 263 SM/J strains 53 . Dosage estimates (expected allele counts) were extracted from the output and 264 used for the GWAS; these estimates captured the degree of uncertainty from the imputation 265 procedure. To ensure the quality of the genotype data, we excluded SNP genotypes with MAF < 266 0.20 and dosage R 2 < 0.70 (dosage R 2 corresponds the estimated square correlation between the 267 allele dosage and the "true allele dosage" from the genetic marker, and is used as a measure of 268 imputation quality). After applying these filters, we retained 434,249 SNPs. The polygenic effect is a random vector which was derived from a multivariate normal 279 distribution with mean zero and a n × n covariance matrix σ 2 λK; where n is the number of samples. 280
The relatedness matrix K was defined by the genotypes. The two parameters, σ 2 and λ, were 281 estimated from the data by GEMMA; they represent the polygenic and residual variance 282 components of the phenotypic variance, respectively. 283 284 Relatedness matrix and proximal contamination 285 We used the genotype data to estimate the relatedness matrix K, which was part of the 286 covariance matrix. Although genotype-based and pedigree-based K matrices yield very similar 287 results 59; 60 , we have shown that in general, genotype-based estimates are more accurate 59; 61-63 . 288
We constructed the relatedness matrix as K = XX ′ /p, where X is the genotype matrix of entries 289
x ij and n × p dimensions, p is the number of SNPs. 290
The relatedness matrix K was estimated taking into account the potential problem of 291 proximal contamination 60 , which involves loss of power due to including genetic markers in multiple 292 components of the LMM equation. Furthermore, because of LD, markers in close proximity to the 293 genetic marker that is being tested can also lead to deflation of the P values 61 . To avoid this 294 problem, the K matrix was estimated by excluding from the calculations the SNPs within the 295 chromosome that was analysed, therefore, K matrix was slightly different for each chromosome. 296 297 Genetic and fixed effects 298 We did not include non-additive effects in the LMMs used for GWAS in the LGSM AIL. Our 299 previous studies 6 suggest that musculoskeletal traits in this population are mostly influenced by 300 additive loci, and by ignoring dominance effects we avoid introducing an additional degree of 301 freedom, hence potentially avoiding a decrease of power to detect QTLs. 302
To analyse the muscle weights of the combined data, we used four fixed effects in the 303 LMM: sex, dissector of the samples, age, and long bone length. We selected these variables after 304 using a linear model to estimate their effect on the four muscles; only statistically significant effects 305 were included (P < 0.01). Sex and dissector were included as binary variables; whereas age and 306 long bone were included as continuous variables. Including long bone length allowed us to capture 307 genetic effects associated with variation in muscle weight per se (as opposed to genetic effects on 308 bone length) 19 . In other words, failing to include long bone as a covariate would yield QTLs that 309 are more likely to be genetic contributors to general growth of the skeleton instead of specifically 310 muscle. We used two bones for the long bone variable, for cohort 1 femur, and for cohorts 2 and 3 311 tibia. Based on personal communication with Dr. Cheverud, the femur and tibia bones were found 312 to be positively and highly correlated (r > 0.8) in LGSM AIL (F34). We did not include generation (r 313 = 1) and bone type of each cohort (r = 1) as fixed effects since the dissector variable functioned as 314 a proxy for these two variables. Body weight was not used as a fixed effect because muscle weight 315 accounts for a considerable amount of the body weight. 316 317 SNP heritability 318 To estimate the SNP heritability or proportion of phenotypic variance explained by all 319 genotypes, we used the n × n realized relatedness matrix K, which was constructed using all the 320 available genotypes. We extracted the SNP heritability from the QTL mapping outputs; GEMMA 321 provides an estimate of the heritability and its standard error 58 The p-values estimated from the likelihood ratio test statistic performed by GEMMA were 327 transformed to -log10 p-values. We calculated a threshold to evaluate whether or not a given SNP 328 significantly contributes to a QTL. We estimated the distribution of minimum p-values under the null 329 hypothesis and selected the threshold of significance to be 100(1 -) th percentile of this 330 distribution, with = 0.05. In order to estimate this distribution, we randomly permuted phenotypes 331 1,000 times, as described previously 6; 7; 19; 64 . We did not include the relatedness matrix in the 332 permutation tests due to computational restrictions, and because, past studies have found that 333 relatedness does not have a major effect on the permutations test 6; 7 . 334
We estimated QTL intervals in three steps. 1) We used Manhattan plots to identify the top 335 SNP within each statistically significant region (SNP with highest -log10 p-values), which we refer to 336 as the peak QTL position. 2) We transformed P values from each analysis to LOD scores (base-10 337 logarithm of the likelihood ratio). 3) We applied the LOD interval function implemented in the r/qtl 338 package 65 to the regions tagged by each peak SNP, and obtained the QTL start and end positions 339 based on the 1.5 LOD score interval. 1.5 LOD intervals are commonly used to approximate the ~ 340 95% confidence interval of mouse QTLs 5; 66 . The 1.5 LOD interval estimation is comparable to the 341 95% CI in the case of a dense marker map 67 ; hence, its coverage depends on the location of the 342 peak QTL marker relative to the adjacent genotyped markers. We estimated the direction of the 343 QTL effect by calculating the phenotypic mean of each allele based on the peak SNP of each QTL. 344
We adjusted the phenotypic means and standard errors by fitting the fixed effects used in the 345 association analyses to a linear model. 346
We explored the QTL intervals to identify genes that potentially affect muscle mass and 347 bone length. We retrieved the genomic location of all genes located within the intervals using the 348 Slides were scanned using Axioscan Z1 slide scanner (Zeiss) using X20 magnification objective. 387
The entire 0.7 cm 2 chamber of a slide or a coverslip was imaged using the wavelength spectrum 388 band of 353-465 nm and 493-517 nm and exposure time 4 ms and 100 ms for DAPI and Alexa 389
Fluor, respectively, at 50% Colibri 7 UV-free LED light source intensity. Alexa Fluor and DAPI 390 channel images of a rectangle area free of artefacts and covering at 14-91% of a chamber of batch 391 1 and 70% of a coverslip of batch 2 were exported separately for analyses with Fiji 69 . Note that the 392 rectangle area of the majority of batch 1 samples (88%), covered more than 40% of the cell 393 culture. The exclusion of small coverage images (14-31%) from the statistical analyses described 394 below, showed results comparable to the analysis of all samples; therefore, we reported 395 significance values (P values) corresponding to the statistical analysis of all samples. 396
Three indices characterising the effect of treatment on myogenesis were quantified in an unbiased, 397 automated analyses of the entire exported area: 1) percentage of fluorescent in the Alexa Fluor 398 channel, reflecting the level of myosin expression, and 2) the longest-shortest-path reflecting the 399 length and number of myotubes ( Figure S4 ). The longest-shortest-path analysis was carried out 400 using the analyse skeleton plugin 70 and the shortest path calculation function 71 implemented in 401 Fiji 69 . We carried out the images analyses on a Linux computer and we allocated 190 GB of RAM 402 memory for these analyses. The myotube threshold was set at 103.97 µm for batch 1 and 191.63 403 µm for batch 2, i.e. the mean (batch 1: 54.34 µm, batch 2:100.95 µm) plus 3 standard deviations 404 (batch 1: SD = 16.54 µm, batch 2: SD = 30.23 µm) of the length of mononucleated and myosin 405 expressing myocytes (n=35) measured in the negative control #1 cells. The myotube length 406 variable did not follow normality, therefore quantile normalization was applied to the variable. All 407 statistical analyses were adjusted for the image area of each sample and batch of cells, by fitting a 408 linear model on the three indices investigated; all subsequent statistical analyses were conducted 409 on the residuals, which met the assumptions of normality and homoscedasticity of residuals. Effect 410 of gene knockdown on these indices was assessed using an ANOVA test to confirm the presence 411 of a statistically significant knockdown effect. After, a T-test was carried out to evaluate the mean 412 differences between the control group and the gene knockdown groups. In addition, we evaluated 413 the myosin expressing area (as percentage of the total) present within in each knockdown versus 414 control groups with an ANOVA test. 415 416 Data availability 417 The human data used for this study can be obtained upon application to the UK biobank project 15 . 418
Results

419
Over 100 genomic loci associated with appendicular lean mass in humans 420 The appendicular lean mass (ALM) ranged from 11.8 to 41.6 kg and 15.3 to 42.5 kg in healthy 421 middle age females and males, respectively (Table 1 ). SNP heritability estimates indicated that 422 35% of phenotypic variability was due to genetic factors. The GWAS analysis revealed 6,150 423 autosomal variants (MAF > 0.001) associated (P < 5 x 10 -8 ) with ALM ( Figure 1 ). The associated 424 variants tagged 293 genes and 385 regulatory elements. We used the Functional Mapping and 425
Annotation of Genome-Wide Association Studies (FUMA GWAS 39 ) to define genomic regions 426 containing the associated variants, and we identified 77 of them that were on average 0.24 Mb 427 long. Furthermore, we conducted a stepwise conditional analysis that partitioned some of the 428 genomic regions and yielded 48 additional independent signals. We refer to the identified regions 429 and the independent signals as loci throughout the text. In total, we identified 125 loci for ALM 430 (Table S5 ) which indicates that ALM is influenced by multiple genetic elements. The LD score 431 intercept that we estimated during this ALM GWAS (1.043 ± 0.007) provides further evidence for 432 polygenicity. Cumulative effects of these loci explained 14.28% of SNP heritability. 433 434 64% of the same loci affect appendicular lean mass in older adults 435 Consistent with the aging effect on skeletal muscle, the ALM in the cohort of elderly 436 declined by 4 and 8% in comparison to the middle-age cohort of females and males, respectively 437 (P < 2×10 -16 ). We then used a 'genetic lean mass score' (see Methods for details) to test if the 438 identified 125 loci contributed to ALM variability in the elderly population. The genetic lean mass 439 score had a statistically significant overall effect (χ 2 = 583.6, df = 4, P = 5.46×10 -125 ) on ALM 440 variability in the elderly population ( Figure 2 ). On average, individuals with the highest genetic lean 441 mass score had 0.90 kg, or 4%, more ALM compared to those with the lowest scores ( Figure 2) . 442
We also found that in some instances negative control iterations resulted in statistically significant 443 (P < 0.05) effects (Table S3 ), however the ALM differences between groups on the negative 444 controls were modest and in the opposite direction of what would be expected (Type III error) 445 ( Figure S3 ). 446
We also asked if the variants identified in the middle-aged cohort were associated with ALM 447 in the elderly. A GWAS in the elderly cohort replicated 4,984 variants based on their P value (P < 5 448 × 10 -8 ) and allelic effect (beta); moreover, the replicated variants tagged 64% of the ALM loci of the 449 middle-aged cohort (two tailed Fisher test P value < 2.2  10 -16 ). Overall, the set of genomic loci in 450 the elderly cohort appeared similar to that of the middle-aged adults, with the exception of an 451 approximately 5 Mb region on chromosome 5 ( Figure S2 ). This region showed a very strong 452 association with the ALM variability in older adults (lowest P value = 3.10  10 -55 , beta = 0.12 ± 453 0.01 kg), and had a modest albeit significant association with the ALM of middle-aged individuals 454 (lowest P value = 3.30  10 -11 ) with an effect size of beta = 0.07 ± 0.01 kg. 455 456 23 QTLs contribute to muscle weight variability in LG/J and SM/J strain-457 derived advanced inter-cross lines. 458 We examined the weight of four hindlimb muscles of the LGSM AIL (F34 and F50-F56): tibialis 459 anterior (TA), extensor digitorium longus (EDL), gastrocnemius and soleus. The LGSM AIL 460 muscles showed extensive individual variability (Table 2) ; furthermore, the SNP heritabilities of the 461 TA, EDL, gastrocnemius and soleus muscles were 0.39, 0.42, 0.31 and 0.30, respectively (Table  462 2). The genome mapping of LGSM AIL muscles yielded 23 QTLs (P < 6.45 × 10 -06 ). The TA, EDL 463 and gastrocnemius QTLs explained more than the 50% of the SNP heritability of each trait (Table  464 S6). The soleus muscle phenotypic variability explained by QTLs was 23% of its SNP heritability. 465 Three QTLs were shared between the four muscles (chromosome 7, 11 and 13; (Figure 3) ; the 466 QTL on chromosome 13 resulted in the strongest association (EDL P = 2.95 × 10 -21 ), with its peak 467 position at 104,435,003 bp, and the percentage of phenotypic variance explained by this locus was 468 5.2%; the SM/J allele conferred increased muscle mass (Figure 3 ). Furthermore, six QTLs were 469 shared between two or three muscles, while fourteen identified QTLs were only associated with 470 one specific muscle (Figure 3) . 471
The mapping resolution was comparable to that attained in the previous study in the LGSM 472 AIL cohort 51 . On average, mouse QTLs were 2.80 Mb long (based on the 1.5 LOD interval) and 473 encompassed 2,259 known genes (Table S7 ). The median number of genes per QTL was 55; 474 more than half of the mouse QTLs enclosed a modest number of genes, however, seven QTLs 475 contained more than 100 genes each, and a single QTL located on chromosome 7 as many as 644 476 genes (Table S6) The ALM mainly consists of the skeletal muscle of the extremities; however, other tissues 483 also contribute. To test the hypothesis that ALM-associated genetic variants primarily affect the 484 skeletal muscle mass, we overlaid the mouse and human findings. This analysis identified five 485 syntenic regions associated with ALM in humans and muscle mass in mice. This analysis 486 permitted us to shorten the list of positional candidates. Assuming the same causative entity for an 487 overlapping mouse and human locus, these five loci harbour only nine homologous genes. 488 Encouragingly, four of these five genomic loci replicated in the ALM of the elderly cohort. 489 490 Selected candidate genes 491 In selection of the candidate genes we focused on the five most robust loci highlighted by 492 both mouse and human GWAS. Out of the nine genes within these five loci (Table 3) , we 493 prioritised the most relevant genes for further testing based on the following information. 494
STC2 495
The STC2 gene had the largest effect size on the ALM in our analyses (beta = 0.877 ± 0.13 496 kg). The minor allele (A) of a missense SNP (rs148833559 (A/C) was associated with the increase 497 in ALM. Prediction tools (SIFT 46 , PolyPhen 72 , CADD 73 , and REVEL 74 ) suggested that the 498 rs148833559 SNP was likely to have a detrimental consequence on STC2 protein structure. 499 Furthermore, STC2 is expressed in human skeletal muscle 48 . 500
SBF2 501
The SBF2 gene is expressed in skeletal muscle 48 and its expression in skeletal muscle is 502 associated with a cis-eQTL 48 . In addition, within the QTL containing the SBF2 gene, we found that 503 the majority of genetic variants associated with ALM were located within SBF2. 504
CPNE1 505
Although little is known about CPNE1, it is an intriguing candidate because a premature 506 stop variant (rs147019139) within the gene was associated with an increase in ALM. Furthermore, 507
Cpne1 was implicated as a positional candidate gene for muscle mass by previous GWAS 508 conducted in outbred (CFW) mice 5 . 509 510 Novel modifiers of in vitro myogenesis 511 We used siRNA-mediated gene knockdown in C2C12 cells to test if candidate genes 512 affected myogenic differentiation. The STC2 75 , CPNE1 (identified as a positional candidate by 513 previous research conducted in CFW mice 5 ) and SBF2 (linked to an aggressive type of Charcot-514
Marie-Tooth disease 76 ) genes were prioritised for this assay. We assessed indices of myogenic 515 differentiation (the number and length of the myotubes, and expression of myosin) of C2C12 cells. 516
In total, 34,989 myotubes were identified and measured in 44 cell cultures (see Methods for 517 details). The gene knockdown had a significant effect on myotube length, with Cpne1 (P = 0.001, 518 95% confidence interval = 0.019-0.068, effect size = 0.024) and Stc2 (P = 0.015, 95% confidence 519 interval= 0.007-0.066, effect size = 0.017) showing an increase in length compared to the control 520 cells (Figure 4 ). There was no significant difference for the Sbf2 gene. The pattern of the effect on 521 myosin expressing area was similar to that of myotube length, however, it did not reach statistical 522 significance (P = 0.21). The number of myotubes was also unaffected. 523 524 Discussion 525
The key findings of the present report are as follows: i) we identified a set of over 100 loci 526 associated with ALM, a substantial expansion in comparison to previous human studies. ii) There 527 is a substantial overlap of the genetic effects between middle aged and elderly subjects. iii) 528
Integration of mouse and human GWAS indicates that skeletal muscle is the primary component 529 affected by the ALM loci, facilitates prioritisation of candidate genes, and helps prediction of their 530 effect on cellular mechanisms. iv) In vitro validation of two genes, CPNE1 and STC2, as novel 531 modifiers of muscle mass in humans. 532
In total, we mapped 125 loci that collectively explain 14.27% of the SNP heritability of ALM. 533
The most recent report, a meta-analysis of 47 independent cohorts (dbGAP), comparable in 534 sample size but ranging in subjects aged 18-to-100 years, reported five significant associations 535 with lean body mass 8 . Even fewer associations were detected in the earlier, small sample size 536 studies 10; 12-14; 77 . However, our results indicate that ALM is a truly polygenic trait in humans. We 537 hypothesize that multiple factors contributed to the improved locus detection in the present GWAS. 538
We restricted subjects' age to a narrow range, 37 to 48 years, minimising the effects of the 539 developmental and aging-related processes on phenotypic variance. The skeletal muscle is a 540 dynamic tissue reaching its peak mass by late 20s, then a trend of decline emerges after 40s and 541 accelerates about two decades later 1 . An estimated 30-50% decline in muscle mass can be 542 expected between 40 and 80 years of age 78 . These developmental and aging-related changes are 543 not linear in progression and therefore would hamper detection of loci even if accounted for in a 544 linear model. We tested the age effect hypothesis in a randomly generated data set of a similar 545 size (n=95,454) which was equally divided between middle-aged and older individuals. A GWAS 546 on ALM in this dataset identified ~ 13% fewer loci (Table S8 ) compared to solely middle-aged 547 adults. This analysis also captured the five loci identified by Zillikens and colleagues 8 , suggesting 548 that the effects of these loci might be less sensitive to the age differences. Hence, our results 549 support the notion of age effect, which is likely to have a large impact with increasing age range. In 550 addition, unlike Zillikens and colleagues 8 , the data set we used was systematically collected as 551 described by the UK Biobank project 15 and we only employed BIA measurements of lean mass. 552
Furthermore, we used a LMM to test the effects of > 17 million variants (MAF > 0.001), and our 553 analysis was adjusted for a different set of fixed effects than in previous research 8; 10; 12; 14 . Hence, 554 a combination of a homogeneous age group, the optimised genomic coverage and the method 555 used to conduct this association analysis contributed to improved detection of loci in the present 556 study. 557
The analyses presented here shed light into the complex genetic mechanisms behind the 558 appendicular muscle mass of humans. In the past, concern was expressed about the 559 reproducibility of association analyses of complex traits; however, an increasing number of human 560 GWAS have shown that their findings are remarkably reproducible 79 . The present study provides 561 further support for the reliability of association studies, demonstrating replication of 64% of ALM 562 loci in the elderly cohort. Furthermore, we show that the genetic profile characterised by depletion 563 of ALM-increasing alleles leads to a lower ALM in elderly individuals (Figure 2 ). Hence, it is 564 conceivable that genetic architecture predisposing individuals to lower muscle mass may lead to 565 elevated risk of sarcopenia 1 . 566 Combining two experimental models, mouse and human, facilitated prioritization of 567 candidate genes for functional validation. To establish the association between the QTGs 568 underlying the identified loci and the muscular phenotype, we focused on the overlapping human 569 and mouse results. Integration of results from these two species permitted circumvention of the 570 limitations imposed by the individual models. While human GWAS often identify associated loci 571 containing single genes, it is often unclear which tissue is most relevant to the phenotype. Although 572 mouse QTLs often contain multiple positional candidate genes, mice can be used as experimental 573 models to identify loci specifically associated with skeletal muscle. In this study, we used a mouse 574 model to show that the association with skeletal muscle mass was specifically related to 575 differences in the cross-sectional area of the constituent muscle fibres, rather than to the number 576 of muscle fibres in the muscle. This is because between the two founders of the LGSM AIL, the 577
LG/J strain compared to the SM/J strain shows over 50% larger cross-sectional area of muscle 578 fibres, but no difference in the number of fibres in soleus muscle 21 . Hence, it is conceivable that the 579 QTGs of the majority of the overlapping loci affected muscle mass specifically via the hypertrophy 580 of muscle fibres. Such prioritization between the two cellular mechanisms of muscle mass 581 variability is important because genes specifically influencing cross-sectional area of muscle fibres 582 can be targeted pharmacologically to prevent and reverse atrophy of muscle fibres in aging 583 muscle 80 . 584 In an effort to validate the specific QTGs and to establish the causality of their effects on 585 skeletal muscle, we tested the siRNA-mediated knockdown effect on myogenesis in vitro. A 586 knockdown of two genes, CPNE1 and STC2, increased the length of the myotubes, implicating an 587 upregulation of myogenic differentiation. We interpret this in vitro observation as consistent with the 588 allelic effect of the locus identified in human GWAS. A nonsense allele within CPNE1 was 589 associated with an increase in ALM in both middle age and elderly populations (Table S9 ). The 590 gene encodes for Copine 1, a soluble calcium-dependent membrane-binding protein 81 that up to 591 date had not been implicated in morphology or function of skeletal muscle. An allele of the second 592 validated gene, STC2, was predicted to have a damaging effect on protein, and was also 593 associated with an increase in ALM. This effect was consistent with overexpression results in a 594 mouse model, showing that transgene animals had substantially reduced muscle mass 75 . The 595 gene encodes Stanniocalcin 2, a homodimeric glycoprotein hormone abundantly expressed in 596 skeletal and cardiac muscle 82 , although mechanisms of its effects on skeletal muscle remain 597 unclear. Collectively these analyses revealed two novel modifiers of myogenesis, which were 598 shown for the first time to be associated with muscle mass variability in humans. 599
In conclusion, the present study capitalised on the advantages of integrating human and 600 mouse GWAS with in vitro validation of causative genes. Our results revealed over 100 genomic 601 loci contributing to ALM in middle-aged humans. The effects of the majority of these loci persist in 602 the elderly population. Integration of human and mouse data also highlighted novel candidate 603 genes affecting skeletal muscle mass in mammals. The plot shows the ALM (kg) of the elderly cohort on the vertical axis. The elderly cohort was 876 ranked by genetic lean mass score and clustered in five quantiles (Q1 to Q5) (horizontal axis). The 877 average genetic lean mass score ( standard error) of each quantile is shown in parenthesis below 878 the horizontal axis. The overall quantile effect of the genetic lean mass score on ALM was tested 879
with Kruskal-Wallis test and the resulting P value is presented on the top of horizontal line above 880 the bars. The ALM median differences between the groups were tested using a Wilcoxon test; the 881 significance level of each comparison is presented above the horizontal lines with a holm adjusted 882 P value. 883 length. The overall effect of the gene knockdown on myotube length was tested using ANOVA and 905 the resulting P value was 0.00017 (F3, 34985 =6.63). Vertical axis represents the myotube length 906 (quantile normalised) residuals (adjusted for area analysed and batch of cells), and the horizontal 907 axis shows control and knockdown gene groups. Boxes represent the distribution of the myotube 908 length for each group. Box whiskers represent minimum and maximum values within 1.5-fold 909 interquartile range above the 75 th percentile and below the 25 th percentile; the box captures 50% of 910 the distribution, and the bold horizontal line represents the median value of the myotube length 911 normalized residuals distribution for each knockdown group. Each red dot represents a single cell 912 culture sample for each knockdown group. Statistically significant t-test P-values between control 913 and knockdown genes are presented above horizontal lines. Effects without a statistically 914 significant difference between the control and gene knockdown are presented as "ns". Cpne1 and 915 Stc2 knockdown groups were not different from each other (P > 0.05). Sbf2 gene knockdown 916 differed from Cpne1 (P = 0.002) and Stc2 (P = 0.043). 917 918 Tables 919 Table 1 . Summary of the middle-aged cohort 920 Column description from left to right: 1) Trait, 2) Number of records, 3) Minimum value within the 921 distribution of each trait, 4) Maximum value within the distribution of each trait, 5) Average value of 922 each trait, 6) Standard deviation, 7) SNP heritability of the ALM across sex. All summary statistic 923 values were calculated for each sex group. ALM: appendicular lean mass. WBF: whole body fat. 924 925 Column description from left to right: 1) Trait, 2) Number of records, 3) Minimum value within the 927 distribution of each trait, 4) Maximum value within the distribution of each trait, 5) Average or mean 928 value of each trait distribution, 6) Standard deviation of the mean, 7) SNP heritability for each trait 929 across sex. Summary statistic values were calculated for each sex group. 930 Column description from left to right: 1) ALM Human locus peak position as "chromosome: base pair position", 2) LGSM QTL peak position as 932 "chromosome: base pair position" (syntenic to human), 3) Elderly cohort P value, 4) Human gene symbol, 5) Human gene name, 6) Adjusted P value 933 of differential expression between the soleus muscle of the LG/J and SM/J mouse strains 24 , 7) Adjusted P value of differential expression between the 934 TA muscle of the LG/J and SM/J mouse strains 24 935
